Effects of phosphodiesterase V (sildenafil) on pulmonary arterial hypertensio
Phase 2
- Conditions
- Pulmonary arterial hypertension
- Registration Number
- JPRN-C000000340
- Lead Sponsor
- Division of cardiovascular internal medicine, The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with PCWP>15mmHg 2. Pregnat women or women of childbearing potential or brestfeeding 3. Patients who are being treated with medicines that contain nitrates 4. Patients who are being treated with phosphodiesterase inhibitors other than sildenafil 5. Patients who are otherwise judged inappropriate for inclusion in the study by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease in pulmonary arterial pressure, pulmonary vascular resistance and increase in cardiac output at 24 weeks after allocation of patients
- Secondary Outcome Measures
Name Time Method Improvement of exercise tolerance (anaerobic threshold and peak VO2) assessed by cardiopulmonary exercise testing